Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?

Area of Science:

• Immunology
• Pharmacology
• Infectious Diseases

Background:

• Targeted and biological therapies have transformed cancer and autoimmune disease treatment.
• Opportunistic infections are well-documented, but bacterial infection risks are less understood.
• Current recommendations for bacterial infection risk are scarce and often based on expert opinion.

Purpose of the Study:

• To review the incidence and risk factors of bacterial infections associated with biological agents.
• To categorize risks based on the mechanism of action of different biological agent groups.
• To provide evidence-based recommendations for managing bacterial infection risks.

Main Methods:

• Systematic review of existing literature.
• Analysis of randomized clinical trials and post-marketing studies.
• Categorization of biological agents by their mechanisms of action.

Main Results:

• Biological agents are associated with a variable risk of bacterial infections.
• Specific risk factors and incidence rates differ across agent classes.
• Limited clear guidelines exist, with some exceptions like meningococcal vaccination for eculizumab users.

Conclusions:

• Further clinical research and real-world studies are needed to fully understand bacterial infection risks.
• Evidence-based recommendations are crucial for safe and effective use of biological therapies.
• Proactive risk management strategies are necessary for patients on biological agents.